Starpharma Pty Ltd
Starpharma is developing a nasal spray for protection against COVID-19 based on the company's proprietary antiviral dendrimer, SPL7013.
Independent testing of SPL7013 has shown potent antiviral and virucidal activity against SARS-CoV-2, the coronavirus that causes COVID-19.
Such a preventative product would provide an additional line of defence, in addition to conventional PPE, including for those in the frontline of this crisis, such as doctors, nurses and other essential workers, and in crowded and high-risk environments, such as public transport and aged care.
A key advantage of this product is that SPL7013 is the active component in Starpharma's range of marketed VivaGel® products and has been shown to be safe and well tolerated in multiple large international clinical trials. This situation enables Starpharma to leverage existing approvals to fast-track regulatory development, with the potential to have a product ready for market within 12 months.
BTB Round: Three
- MTPConnect Grant: $1,103,750
- Industry Contribution: $2,154,170
Duration: September 2020 – August 2021
Visit Starpharma for more information | Twitter: @Starpharma_ASX | LinkedIn: Starpharma
Contact: Dr Jeremy Paull
Podcast: Spotlight: Starpharma’s COVID-19 Nasal Spray for UK & Europe (5 March 2021)